Cell-Safe™ for Islet Transplantation
Type 1 Diabetes
Pre-clinicalActive
Key Facts
About Cell-Safe Life sciences
Cell-Safe Life Sciences is pioneering a novel approach to cell therapy with its active implantable immunoisolation device. The Cell-Safe™ system is designed to overcome critical hurdles in cell transplantation, including immune rejection, hypoxia, and the inability to monitor or replenish cells, by providing a self-nourishing, reloadable chamber. Founded in 2017 and based in Boston, the company is in the pre-clinical stage, focusing first on an application for type 1 diabetes. Its technology represents a potential paradigm shift for cell replacement therapies across multiple indications.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |